Pembrolizumab Injection [Keytruda]

Phase 1

Pembrolizumab Injection [Keytruda] is one of 4 therapeutic programs targeting Advanced Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced MelanomaActive, not recruiting

Advanced MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Advanced Melanoma

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 2

1 2

Leukine

Sanofi

Phase 2

1 3

Glucophage

EMD Serono

Phase 1

1 4

Pembrolizumab Injection [Keytruda]

YYana Najjar

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Active, not recruiting

Advanced Melanoma

NCT03311308

Clinical

Trials by Indication[1]

Advanced Melanoma1 trial

Profiling and Reversing Metabolic Insufficiency in the Tumor Microenvironment in Advanced Melanoma: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Active, not recruiting·YYana Najjar·Phase 1·NCT03311308·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pembrolizumab Injection [Keytruda]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pembrolizumab Injection [Keytruda]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Yana Najjar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: YYana Najjar

Pembrolizumab Injection [Keytruda]

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Advanced Melanoma1 trial

References

Drug Info

Quick Facts

Related News